RT Journal Article
SR Electronic
T1 Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.10.22278639
DO 10.1101/2022.08.10.22278639
A1 Carolin Otto
A1 Tatjana Schwarz
A1 Lara M. Jeworowski
A1 Marie L. Schmidt
A1 Felix Walper
A1 Florence Pache
A1 Patrick Schindler
A1 Moritz Niederschweiberer
A1 Andi Krumbholz
A1 Ruben Rose
A1 Christian Drosten
A1 Klemens Ruprecht
A1 Victor M Corman
YR 2022
UL http://medrxiv.org/content/early/2022/08/11/2022.08.10.22278639.abstract
AB Background Humoral immune responses to COVID-19 vaccination are diminished in anti-CD20 treated patients with multiple sclerosis (pwMS). In healthy individuals, neutralizing antibodies against the SARS-CoV-2 Omicron variant are only detected after three COVID-19 vaccinations. It was hitherto unknown whether a third or fourth COVID-19 vaccination of anti-CD20 treated pwMS improves SARS-CoV-2 specific humoral immune responses, including neutralizing antibodies against Omicron.Methods Anti-CD20 treated pwMS vaccinated two (n=61), three (n=57) or four (n=15) times and healthy controls (n=10) vaccinated thrice were included in a prospective cohort study. Anti-SARS-CoV-2 spike S1 IgG and IgA levels, maturation of SARS-CoV-2 IgG avidity, neutralizing capacity against the SARS-CoV-2 Omicron BA.2 variant and SARS-CoV-2 specific T cell responses were analyzed.Results The proportion of anti-CD20 treated pwMS with detectable SARS-CoV-2 S1 IgG was similar after the second (31/61, 50.8%), third (31/57, 54.4%) and fourth (8/15, 53.3%) vaccination. In pwMS with detectable SARS-CoV-2 IgG, the proportion with high affinity antibodies increased from the second (6/31, 19.4%) to the third (17/31, 54.8%) and fourth (6/8, 75%) vaccination. While none (0/10) of the anti-CD20 treated pwMS vaccinated twice had Omicron specific neutralizing antibodies, 3/10 (30%) pwMS vaccinated thrice and 3/5 (60%) pwMS vaccinated four times generated Omicron specific neutralizing antibodies.Conclusion Although SARS-CoV-2 specific humoral immune responses remain quantitatively impaired, in those anti-CD20 treated pwMS who do develop SARS-CoV-2 antibodies, the functionality of SARS-CoV-2 antibodies, including neutralizing antibodies against Omicron, improves after three and four SARS-CoV-2 vaccinations, supporting current recommendations for one or two booster vaccination in anti-CD20 treated pwMS.Competing Interest StatementVMC is named together with Euroimmun GmbH on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. KR is site principal investigator in clinical trials sponsored by Roche, the manufacturer of ocrelizumab and rituximab, and received research support from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charite and Arthur Arnstein Foundation, and travel grants from Guthy Jackson Charitable Foundation. All other authors declare no disclosures relevant to the manuscript.Funding StatementParts of this work were supported by grants from the Berlin Institute of Health (BIH) and Berlin University Alliance to C.D. and V.M.C. This study was further supported by the German Ministry of Education and Research through Forschungsnetzwerk der Universitaetsmedizin zu COVID-19, COVIM, FKZ: 01KX2021 to C.D. and V.M.C., and projects VARIPath (01KI2021) to V.M.C. F.P. and V.M.C. are participants in the BIH-Charite Clinician Scientist Program funded by Charite - Universitaetsmedizin Berlin and the Berlin Institute of Health. K.R. is a participant in the BIH Clinical Fellow Program funded by Stiftung Charite.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committee of Charite - Universitaetsmedizin Berlin (EA2/152/21 and EA1/068/20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.